27
Mon, May
76 New Articles

White & Case and Greenberg Traurig Advise on Celon Pharma's PLN 216 Million SPO

White & Case and Greenberg Traurig Advise on Celon Pharma's PLN 216 Million SPO

Poland
Tools
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

White & Case has advised Celon Pharma S.A. on its second public offering of 6 million series D shares. Greenberg Traurig advised global coordinators and joint book-runners Dom Maklerski Banku Handlowego, Citigroup Global Markets Europe, Erste Group Bank AG, and Erste Securities Polska, joint book-runners Jefferies GmbH and Jefferies International Limited, and co-lead manager Trigon Dom Maklerski.

Celon Pharma is a Polish biopharmaceutical company that develops and sells pharmaceutical products. 

According to White & Case, as a result of the issuance, Celon Pharma raised a total of PLN 216 million for the development and commercialization of its most advanced projects in the clinical development stage. The shares were split as 3.1% offered to retail investors and 96.9% offered to institutional investors.

White & Case’s team included Warsaw-based Partner Marcin Studniarek and Associates Monika Duzynska and Dawid Ksiazek, as well as London-based Partners Jill Christie and Inigo Esteve and counsel Doron Loewinger.  

Greenberg Traurig’s team consisted of Warsaw-based Partner Rafal Sienski and Associates Michal Baldowski and Lukasz Chmura and London-based Partners Dorothee Fischer-Appelt and James Mountain.

Our Latest Issue